Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

por Slingluff Craig L, Brautigan David L, Molhoek Kerrington R
Publicado 2005-10-01

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

por Molhoek, Kerrington R, Brautigan, David L, Slingluff, Craig L
Publicado 2005

Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma

por Shada, Amber L., Molhoek, Kerrington R., Slingluff, Craig L.
Publicado 2010

Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T Cell Receptor and is modulated by IL-2

por Molhoek, Kerrington R., McSkimming, Chantel C., Olson, Walter C., Brautigan, David L., Slingluff, Craig L.
Publicado 2008

Human melanoma cytolysis by combined inhibition of mTOR and VEGF/VEGFR-2

por Molhoek, Kerrington R., Griesemann, Heinrich, Shu, Jianfen, Gershenwald, Jeffrey E., Brautigan, David L., Slingluff, Craig L.
Publicado 2008

Comprehensive analysis of RTK activation in human melanomas reveals autocrine signaling through IGF-1R

por Molhoek, Kerrington R., Shada, Amber L., Smolkin, Mark, Chowbina, Sudhir, Papin, Jason, Brautigan, David L., Slingluff, Craig L.
Publicado 2011

Evaluation of Molecular Markers of Mesenchymal Phenotype in Melanoma

por Mikesh, Leann M., Kumar, Manish, Erdag, Gulsun, Hogan, Kevin T., Molhoek, Kerrington R., Mayo, Marty W., Slingluff, Craig L.
Publicado 2010

VEGFR-2 Expression in Human Melanoma: Revised Assessment

por Molhoek, Kerrington R., Erdag, Gulsun, Rasamny, Jk, Murphy, Cheryl, Deacon, Donna, Patterson, James W., Slingluff, Craig L., Brautigan, David L.
Publicado 2011

MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab

por Wagenseller, Aubrey G, Shada, Amber, D’Auria, Kevin M, Murphy, Cheryl, Sun, Dandan, Molhoek, Kerrington R, Papin, Jason A, Dutta, Anindya, Slingluff Jr, Craig L
Publicado 2013

The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides

por Harris, Rebecca C., Chianese-Bullock, Kimberly A., Petroni, Gina R., Schaefer, Jochen T., Brill, Louis B., Molhoek, Kerrington R., Deacon, Donna H., Patterson, James W., Slingluff, Craig L.
Publicado 2012

Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial (CTEP 7190/Mel47)

por Slingluff, Craig L., Petroni, Gina R, Molhoek, Kerrington R., Brautigan, David L., Chianese-Bullock, Kimberly A., Shada, Amber L., Smolkin, Mark E., Olson, Walter C., Gaucher, Alison, Chase, Cheryl Murphy, Grosh, William W., Weiss, Geoffrey R., Wagenseller, Aubrey G., Olszanski, Anthony J., Martin, Lainie, Shea, Sofa M., Erdag, Gulsun, Ram, Prahlad, Gershenwald, Jeffrey E., Weber, Michael J.
Publicado 2013